Effect of dulaptide combined with dapagliflozin and telmisartan in the treatment of diabetes mellitus complicating with cardiorenal insufficiency

Objective To explore the effectiveness and safety of dulaptide combined with dagliflozin and telmisartan in the treatment of diabetes mellitus complicating with cardiorenal insufficiency and its effects on blood glucose levels and cardiac function.

Methods A total of 110 patients with type diabetes combined with cardiorenal dysfunction were selected as study objects, and were divided into study group and control group according to random number table method, with 55 cases in each group. The control group orally administrated Dagliazine Tablets and Telmisartan Tablets, while the study group received dulaglutide injection based on the treatment of the control group. Both groups were treated for 3 months. Blood nitrogen (BUN), uric acid (UA), left heart ejection fraction (LVEF), left ventricular end-diastolic diameter (LVEDD), plasma amino-terminal brain natriuretic peptide precursor (NT-proBNP), HbA1c (HbA1c), 2 h postprandial blood glucose (2 hPG), fasting blood glucose (FPG) were measured, and the glomerular filtration rate (GFR) and urinary protein excretion rate were calculated. The efficacy and safety were evaluated in both groups.

Results After treatment, urinary protein excretion rate and BUN, UA, 2 hPG, FPG, HbA1c, NT-proBNP levels in two groups were lower than before treatment, and above indicators in the study group were lower than those in the control group(P < 0.05). After treatment, GFR and LVEF levels in two groups were higher than before treatment, and were higher in the study group than those in the control group (P < 0.05). After treatment, the values of LVEDD in two groups were lower than before treatment, and LVEDD was lower in the study group than that in the control group (P < 0.05). The total effective rate of the study group was 92.73%, which was higher than 76.36% of the control group (P < 0.05). There was no significant difference in the total incidence of adverse reactions between the two groups (χ²=0.910, P=0.340).

Conclusion Compared with daglipin combined with telmisartan, dulaptide combined with dapagliflozin and telmisartan can reduce blood glucose level, improve cardiac and renal indexes, and have higher therapeutic effectiveness and safety in treating diabetic patients with cardiac and renal insufficiency.